ABI Launches New Mass Specs as It Tries To Turn MS Biz Around and Stay On Top

The announcement by ABI/MDS marks the partners’ most significant mass-spec introduction in more than three years, and ends a technology drought that had dragged down ABI’s mass spec business for the past 18 months. The partners hope the launches will revive the mass spec business.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.